Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in AdolescentsRobert W. Frenck, William C. Gruber, John L. Perez et al.|New England Journal of Medicine|2021Cited by 937
Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-oldRobert W. Frenck, William C. Gruber, Nicola P. Klein et al.|Future Virology|2023Cited by 3
Bivalent RSVpreF Subunit Vaccine Safety and Immunogenicity in Seropositive 2–<18 Year OldsJulia R. Glanternik, Iona Munjal, Grant Paulsen et al.|Vaccines|2026Cited by 0